EP Wealth Advisors LLC Invests $483,000 in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

EP Wealth Advisors LLC purchased a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,191 shares of the company’s stock, valued at approximately $483,000.

Several other institutional investors and hedge funds also recently made changes to their positions in NBIX. Ashton Thomas Private Wealth LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter worth about $28,000. Innealta Capital LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter worth about $30,000. EdgeRock Capital LLC purchased a new stake in Neurocrine Biosciences during the 2nd quarter worth about $35,000. Blue Trust Inc. lifted its holdings in Neurocrine Biosciences by 171.9% during the 3rd quarter. Blue Trust Inc. now owns 348 shares of the company’s stock worth $40,000 after purchasing an additional 220 shares in the last quarter. Finally, Plato Investment Management Ltd lifted its holdings in Neurocrine Biosciences by 44.1% during the 2nd quarter. Plato Investment Management Ltd now owns 425 shares of the company’s stock worth $59,000 after purchasing an additional 130 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Trading Down 1.1 %

Shares of Neurocrine Biosciences stock opened at $126.79 on Friday. The business’s 50-day moving average price is $121.49 and its 200-day moving average price is $130.78. Neurocrine Biosciences, Inc. has a 12 month low of $110.95 and a 12 month high of $157.98. The firm has a market capitalization of $12.84 billion, a PE ratio of 33.99 and a beta of 0.34.

Insider Buying and Selling

In related news, insider Jude Onyia sold 2,331 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $126.29, for a total transaction of $294,381.99. Following the transaction, the insider now directly owns 15,449 shares in the company, valued at $1,951,054.21. This trade represents a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.30% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

NBIX has been the topic of a number of recent research reports. HC Wainwright reissued a “buy” rating and set a $190.00 price objective on shares of Neurocrine Biosciences in a report on Friday, November 1st. Needham & Company LLC reissued a “hold” rating on shares of Neurocrine Biosciences in a report on Monday, November 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. StockNews.com cut Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a report on Friday, November 1st. Finally, Jefferies Financial Group raised their price target on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a “buy” rating in a report on Monday, August 19th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $165.18.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.